A practical reference on vaccine adjuvant: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
==== European Union ==== In February 2016, orphan designation (EU/3/16/1615) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for remdesivir for the treatment of Ebola virus disease. In April 2020, the European Medicines Agency (EMA) provided recommendations on compassionate use of remdesivir for COVID‑19 in the EU. In May 2020, the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended expanding the compassionate use of remdesivir to those not on mechanical ventilation. In addition to those undergoing invasive mechanical ventilation, the compassionate use recommendations cover the treatment of hospitalized individuals requiring supplemental oxygen, non-invasive ventilation, high-flow oxygen devices or ECMO (extracorporeal membrane oxygenation). The updated recommendations were based on preliminary results from the NIAID-ACTT study, which suggested a beneficial effect of remdesivir in the treatment of hospitalized individuals with severe COVID‑19. In addition, a treatment duration of five days was introduced alongside the longer ten-day course, based on preliminary results from another study (GS-US-540-5773) suggesting that for those not requiring mechanical ventilation or ECMO, the treatment course may be shortened from ten to five days without any loss of efficacy. Individuals who receive a five-day treatment course but do not show clinical improvement will be eligible to continue receiving remdesivir for an additional five days.
==== Biophysics of AMPA receptor trafficking ==== The movement of AMPA receptors within the neuronal membrane is commonly modeled as Brownian diffusion, reflecting their lateral mobility across the lipid bilayer. However, at synaptic sites— particularly the postsynaptic density (PSD)—this motion is modulated by retention forces that can transiently stabilize receptors. These forces do not completely immobilize AMPARs but instead permit a dynamic exchange with receptors in the perisynaptic domain. The molecular basis for this stabilization is believed to involve nanodomain organization within the PSD, including anchoring interactions with scaffolding proteins such as PSD-95 and transmembrane AMPA receptor regulatory proteins (TARPs). Recent evidence suggests that this compartmentalization may arise through liquid-liquid phase separation (LLPS), a biophysical process by which biomolecular condensates form via weak, multivalent interactions. LLPS may contribute to the formation of synaptic nanodomains that selectively retain or enrich AMPARs at functional sites within the PSD.
== Post-translational modifications == Human C3orf52 is predicted to contain three phosphorylation sites at positions 140,180, and 183, two N-glycosylation sites at positions 106 and 159, and three O-linked glycosylation sites at positions 7, 26, and 37. All of the O-linked glycosylation sites are within the disordered region of this protein. This indicates that C3orf52 is a moderately regulated protein that likely functions more as a scaffold than as a structural protein.
In April 2013, Hird, as coach, was accused of being personally injected with supplements in 2011 and 2012 that would be deemed performance enhancing if he were a player. Essendon players from 2011 and 2012 were also accused of ingesting performance enhancing supplements. As head coach, Hird was subsequently implicated. Following months of rumours and investigations, on 13 August 2013, Hird, along with the Essendon Football Club, senior assistant coach Mark Thompson, football manager Danny Corcoran and club doctor Bruce Reid, was charged by the AFL with bringing the game into disrepute in relation to the poor governance of the supplements program at the club in 2011 and 2012. The club was given 14 days to consider the charges and faced an AFL Commission hearing on 26 August 2013. On 27 August 2013, following much negotiation, Hird accepted charges that he had brought the game into disrepute and abandoned possible Supreme Court action against the AFL and its chief executive, Andrew Demetriou. He maintained that he did little wrong, but said he should have known more about the club's supplements program. He was banned from working at any AFL club in any capacity for twelve months commencing from 25 August 2013. Hird was allowed to attend Essendon matches as a spectator during this period. However, despite not being allowed to pay him for working as a coach during 2014, the club paid Hird $1 million in advance for 2014 in December 2013. A media report on 3 October 2013 said that Hird denied pleading guilty for a reduced charge as alleged by Demetriou.
In the United States, the Federal Food, Drug, and Cosmetic Act defines what substances, known as legend drugs, require a prescription for them to be dispensed by a pharmacy. The federal government authorizes physicians (of any specialty), physician assistants, nurse practitioners and other advanced practice nurses, veterinarians, dentists, and optometrists to prescribe any controlled substance. They are issued unique DEA numbers. Many other mental and physical health technicians, including basic-level registered nurses, medical assistants, emergency medical technicians, most psychologists, and social workers, are not authorized to prescribe legend drugs. The federal Controlled Substances Act (CSA) was enacted in 1970. It regulates manufacture, importation, possession, use, and distribution of controlled substances, which are drugs with potential for abuse or addiction. The legislation classifies these drugs into five schedules, with varying qualifications for each schedule. The schedules are designated schedule I, schedule II, schedule III, schedule IV, and schedule V. Many drugs other than controlled substances require a prescription. The safety and the effectiveness of prescription drugs in the US are regulated by the 1987 Prescription Drug Marketing Act (PDMA). The Food and Drug Administration (FDA) is charged with implementing the law. As a general rule, over-the-counter drugs (OTC) are used to treat a condition that does not need care from a healthcare professional if have been proven to meet higher safety standards for self-medication by patients.
Sources: en.wikipedia.org
Piperidine is an organic compound with the molecular formula (CH2)5NH. This heterocyclic amine consists of a six-membered ring containing five methylene bridges (–CH2–) and one amine bridge (–NH–). It is a colorless liquid with an odor described as objectionable, human sperm-like, typical of amines. The name comes from the genus name Piper, which is the Latin word for pepper. Although piperidine is a common organic compound, it is best known as a representative structure element within many pharmaceuticals and alkaloids, such as naturally-occurring solenopsins.
2-, alpha-, or α-amino acids have the generic formula H2NCHRCOOH in most cases, where R is an organic substituent known as a "side chain". Of the many hundreds of described amino acids, 22 are proteinogenic ("protein-building"). It is these 22 compounds that combine to give a vast array of peptides and proteins assembled by ribosomes. Non-proteinogenic amino acids may arise through nonribosomal peptide synthesis. Modified amino acids, by contrast, typically result from post-translational modification.
=== Slang terms === Slang terms for alprazolam vary by geographic location. Some of the more common terms are modified versions of the trade name "Xanax", such as Xannies (or Xanies) and the phonetic equivalent of Zannies; references to their drug classes, such as benzos or downers; or remark upon their shape or color (most commonly a straight, perforated tablet or an oval-shaped pill): bars, ladders, Xanbars, Xans, Z-bars, handlebars, beans, footballs, schoolbuses, planks, poles, sticks, blues, totem poles, or blue footballs.
Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist. Terlipressin was approved for medical use in the United States in 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
Genetic research has produced several genetically modified varieties. 'New Leaf', owned by Monsanto Company, incorporates genes from Bacillus thuringiensis (source of most Bt toxins in transcrop use), which confers resistance to the Colorado potato beetle; 'New Leaf Plus' and 'New Leaf Y', approved by US regulatory agencies during the 1990s, also include resistance to viruses. McDonald's, Burger King, Frito-Lay, and Procter & Gamble announced they would not use genetically modified potatoes, and Monsanto published its intent to discontinue the line in March 2001. Potato starch contains two types of glucan, amylose and amylopectin, the latter of which is most industrially useful. Waxy potato varieties produce waxy potato starch, which is almost entirely amylopectin, with little or no amylose. BASF developed the 'Amflora' potato, which was modified to express antisense RNA to inactivate the gene for granule bound starch synthase, an enzyme which catalyzes the formation of amylose. 'Amflora' potatoes therefore produce starch consisting almost entirely of amylopectin, and are thus more useful for the starch industry. In 2010, the European Commission cleared the way for 'Amflora' to be grown in the European Union for industrial purposes only—not for food. Nevertheless, under EU rules, individual countries have the right to decide whether they will allow this potato to be grown on their territory. Commercial planting of 'Amflora' was expected in the Czech Republic and Germany in the spring of 2010, but due to lack of acceptance BASF in 2012 stopped selling the variety in Europe.
Tim Hortons is popularly known as "Timmies" or "Timmy's". The ubiquity of Tim Hortons, through the wide expansion of its outlets, makes it a prominent feature of Canadian life; Canadians eat more donuts per capita and have more donut outlets per capita than any other nation. Tim Hortons' prevalence in the coffee and donut market has led to its branding as a Canadian cultural icon. The media routinely refer to its iconic status, despite this being a relatively recent development; there were only a few outlets before the chain's expansion in the late 1990s and 2000s. A series of Tim's television commercials promotes this idea by showing vignettes of Canadians abroad and their homesickness for Tim Hortons. Canadian author Pierre Berton once wrote: "In so many ways the story of Tim Hortons is the essential Canadian story. It is a story of success and tragedy, of big dreams and small towns, of old-fashioned values and tough-fisted business, of hard work and of hockey." Commentator Rex Murphy posited that the reason Tim Hortons "transmuted into a hallowed piece of Canadiana" was perhaps consumers' "reverse-preference" against the sudden penetration of Starbucks in the 1990s. Other commentators have bemoaned the rise of Tim Hortons as a national symbol.
==== Myanmar earthquake, March 2025 ==== President Trump stated the United States would help in response to the March 28 earthquake in Myanmar, although the question was asked by a former USAID executive of whether or not the United States will beat other countries in getting there with a relief team(s).
== Normal amount == In a urinalysis, the normal amount of urinary calcium can be measured in amount per time (commonly per 24 hours). It can also be measured in amount per mass of creatinine, which avails for estimating the urinary calcium excretion in a spot urine sample, because urinary creatinine clearance is relatively unaffected by differences in free water clearance which occurs, for example, in dehydration and which would distort the interpretation of the urinary calcium in a spot urine sample. Normally, in an average adult, the amount of calcium excreted in the urine is 100–250 mg over a 24-hour period. For those on low-calcium diets, there is normally 50–150 mg/24 hours, while those on a calcium-free diet will have 5–40 mg/24 hours. The following reference ranges are for persons with average calcium intake (600–800 mg/day for adults):
Thus, these algorithms provide a good perspective on the different kinds of algorithms available for protein design. In 2020 scientists reported the development of an AI-based process using genome databases for evolution-based designing of novel proteins. They used deep learning to identify design-rules. In 2022, a study reported deep learning software that can design proteins that contain pre-specified functional sites.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.